Stockreport

GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows

GlaxoSmithKline PLC  (GSK) 
US:NYSE Investor Relations: gsk.com/en-gb/investors
PDF Reduction observed in RSV-related hospitalizations in adults aged =60 years1An observed reduction in major adverse cardiovascular events* in adults aged =60 years?2 duri [Read more]